Health · Cancer Treatment
New Mesothelioma Treatments in 2026: Immunotherapy, Surgery and Breakthrough Therapies
Mesothelioma was long considered one of the hardest cancers to treat, with very limited options. That picture is changing. Immunotherapy, refined surgery, tumor-treating fields and a wave of experimental therapies are giving patients more choices — and, in some cases, more time. Here is a clear, up-to-date guide to the newest mesothelioma treatments and what they mean for patients and families.
Understanding mesothelioma in brief
Mesothelioma is an aggressive cancer of the lining of the lungs (pleural mesothelioma) or abdomen (peritoneal mesothelioma), caused almost exclusively by past asbestos exposure. Because it can take 20 to 40 years to develop after exposure, most patients are diagnosed at an older age and at an advanced stage. More than 30,000 new cases are estimated worldwide each year. Historically, median survival ranged from roughly 8 to 22 months, which is exactly why the recent treatment advances described below matter so much.Immunotherapy: the new first-line standard
The biggest shift in mesothelioma care has been the rise of immunotherapy, which helps the body’s own immune system recognize and attack cancer cells. The combination of two immune checkpoint inhibitors, nivolumab (Opdivo) plus ipilimumab (Yervoy), is now approved by the U.S. FDA and the European Medicines Agency as a first-line treatment for unresectable (inoperable) malignant pleural mesothelioma. This approval was driven by the landmark CheckMate-743 trial, in which the immunotherapy combination outperformed standard chemotherapy on overall survival, with roughly four in ten patients alive at two years. Longer follow-up has continued to show a survival edge over chemotherapy alone. In 2025, regulators also approved a subcutaneous (injectable) form of nivolumab, allowing many patients to receive treatment in minutes rather than through longer intravenous infusions. Researchers are now testing immunotherapy earlier in the disease. A 2025 phase 2 trial explored giving nivolumab, alone or with ipilimumab, around the time of surgery in patients with operable pleural mesothelioma, using blood-based “ctDNA” testing to track response. It is worth noting one nuance: some recent reviews suggest the benefit of immunotherapy may be smaller in the epithelioid subtype, the most common form, so treatment is increasingly tailored to the individual.Nivolumab plus ipilimumab is now a first-line standard for inoperable pleural mesothelioma — the first major treatment shift in this cancer in years.
Surgery: a more selective, refined approach
Surgery remains an option for carefully chosen patients, but the thinking has evolved. The two main operations are pleurectomy/decortication (P/D), which removes the diseased lining while sparing the lung, and the more aggressive extrapleural pneumonectomy (EPP), which removes the lung itself. The MARS 2 trial found no survival benefit from extensive lung-removal surgery and noted more complications, leading many specialists to favor lung-sparing surgery and to reserve major operations for highly selected cases at experienced mesothelioma centers. The takeaway for patients: surgery can still play a role, but it should be discussed carefully with a specialized multidisciplinary team rather than assumed to be the best path.Chemotherapy: still a treatment backbone
Chemotherapy continues to play a central role, often combined with the newer options above. The standard regimen pairs cisplatin (or carboplatin) with pemetrexed, sometimes alongside the anti-angiogenic drug bevacizumab. Chemotherapy may be used before or after surgery, or as a primary treatment when surgery and immunotherapy are not suitable.Tumor-Treating Fields (TTFields)
A newer, non-invasive option is Tumor-Treating Fields, delivered through a wearable device (marketed as Optune Lua / NovoTTF). It uses low-intensity electric fields applied to the chest to disrupt cancer cell division. When combined with chemotherapy, TTFields received FDA authorization for unresectable pleural mesothelioma, based on the STELLAR study. Because it is worn rather than infused or implanted, it appeals to patients seeking options with fewer systemic side effects.Emerging and experimental treatments to watch
Some of the most exciting developments are still in clinical trials, but they point to where mesothelioma care is heading:- CAR-T cell therapy: a patient’s own immune cells are engineered to target mesothelin, a protein found on many mesothelioma cells. Early-phase trials have shown encouraging signals.
- Oncolytic virotherapy: viruses modified to attack tumors. MVdeltaC, a modified measles virus injected directly into tumors, received FDA orphan drug designation in 2025; ONCOS-102, a modified adenovirus, has been studied with chemotherapy.
- Cancer vaccines and dendritic cell therapy: approaches designed to “train” the immune system against mesothelioma cells.
- Targeted and combination therapies: drugs aimed at specific molecular features of the tumor, often paired with immunotherapy to boost response.
Peritoneal mesothelioma: HIPEC and PIPAC
For mesothelioma in the abdomen, a combined approach of surgery plus heated intraperitoneal chemotherapy (HIPEC) has produced some of the longest survival times in selected patients, with reported median survival of several years at specialized centers. A gentler, repeatable technique called PIPAC (pressurized intraperitoneal aerosol chemotherapy) is also being studied for patients who are not candidates for major surgery.Clinical trials: how to access the newest treatments
Many of the breakthroughs above are available only through clinical trials. Joining a trial can give patients access to cutting-edge therapies before they are widely approved. Patients and caregivers can ask their oncology team about open trials, or search reputable databases such as the U.S. National Cancer Institute and ClinicalTrials.gov. Treatment at a dedicated mesothelioma center, where specialists see this rare cancer regularly, is consistently linked to better-informed care.Earlier detection and blood biomarkers
Catching mesothelioma sooner improves the odds that newer treatments will help. Researchers are developing blood biomarkers — including soluble mesothelin-related peptides (SMRPs) and fibulin-3 — that may one day detect the disease earlier in people with a history of asbestos exposure, sometimes before it appears on scans. These tests are promising but still largely investigational.Questions to ask your care team
- Which mesothelioma type and subtype do I have, and how does that affect my options?
- Am I a candidate for immunotherapy, surgery, TTFields, or a combination?
- Is treatment at a specialized mesothelioma center recommended for my case?
- Are there clinical trials I may qualify for, locally or nationally?
- What are the realistic benefits and side effects of each option for someone in my situation?
How doctors choose the right mesothelioma treatment
There is no single “best” mesothelioma treatment — the right plan depends on the cancer’s location (pleural or peritoneal), its cell subtype (epithelioid, sarcomatoid or biphasic), the stage at diagnosis, and the patient’s overall health and preferences. Increasingly, care is multimodal, meaning two or more approaches are combined, such as surgery followed by chemotherapy, or chemotherapy paired with immunotherapy or tumor-treating fields. Tumor profiling and biomarkers like PD-L1 may also help guide which therapies are most likely to work. This is why a multidisciplinary team — including thoracic or surgical oncologists, medical oncologists, radiologists and palliative-care specialists — is so important. Patients are often encouraged to seek a second opinion at a high-volume mesothelioma center, where doctors have deep experience with this rare cancer and access to the latest trials.Managing side effects and quality of life
Alongside treatments aimed at the cancer itself, supportive (palliative) care plays a vital role in helping patients feel better and stay active. This can include procedures to drain fluid and ease breathlessness, pain management, nutrition support and emotional or psychological help for patients and families. Importantly, palliative care is not the same as end-of-life care — it can be provided at any stage and works hand in hand with active treatment to improve quality of life.Frequently asked questions about new mesothelioma treatments
What is the newest treatment for mesothelioma?
The most significant recent change is the FDA-approved immunotherapy combination of nivolumab and ipilimumab for inoperable pleural mesothelioma. Newer options under study include CAR-T cell therapy targeting mesothelin and oncolytic virus therapies.Can immunotherapy cure mesothelioma?
Immunotherapy is not currently a cure, but for some patients it has extended survival and improved quality of life compared with chemotherapy alone. Results vary by individual and by mesothelioma subtype.Is surgery still recommended for mesothelioma?
Surgery can help carefully selected patients, but recent evidence has shifted specialists toward lung-sparing surgery and away from the most aggressive lung-removal operations for most people. Decisions should be made with a specialized team.How can I access experimental mesothelioma treatments?
Mainly through clinical trials. Ask your oncologist about eligibility, and explore trusted databases such as ClinicalTrials.gov and the National Cancer Institute, ideally with the help of a mesothelioma specialist.What is the life expectancy with new mesothelioma treatments?
Outcomes depend on stage, subtype, overall health and treatment. While historical median survival was often under two years, newer combinations have improved survival rates for some patients, and selected peritoneal mesothelioma patients treated with surgery and HIPEC have lived considerably longer.This article is for general informational purposes only and is not medical advice. Mesothelioma treatment is highly individual; only a qualified oncology team can recommend the right plan for a specific patient. Anyone diagnosed with mesothelioma should consult a specialist promptly, as treatment options and clinical-trial availability change over time.